Biobanking Equipment Market is estimated to be valued at USD 3.7 Bn in 2025 and is expected to reach USD 7.88 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 11.4% from 2025 to 2032.
Biobanking is the organized way to collect, record, store and keep samples of blood, tissue, urine, DNA, RNA and cells which will be used for scientific research later. Information on health and demographics forms a natural part of bio samples which support researchers in their investigations of diseases, hereditary traits and how patients respond to different treatments. Biobanks focus on populations or certain diseases and are key to making studies take longer, improving research results and finding new approaches for diagnosing and treating diseases.
|
Current Events |
Description and its impact |
|
Geopolitical Uncertainty and Regional Market Dynamics
|
|
|
Technological Innovation and Digitalization in Biobanking Equipment |
|
|
Climate Change and Sustainability Initiatives |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Artificial intelligence (AI) is changing biobanking equipment by making automation, data handling, and maintenance much easier. This helps solve big problems in storing and finding samples. Traditional biobanking systems often struggle with managing large and complex amounts of data, but AI tools make these tasks faster and more efficient.
A major way AI helps is by automatically organizing and updating information about samples, called metadata. For example, Verisense Health’s Digital Biobank™ uses an AI-powered system to do this for millions of samples. This reduces mistakes and makes data easier to access, which is very important when dealing with huge collections of samples.
Biobanking equipment is on the rise owing to the growing use of cutting-edge technologies like automation, ultra-low temperature freezers, and liquid nitrogen tanks that are crucial for keeping biological samples intact over long periods. These tools are essential for preserving the integrity and viability of biological samples including blood, tissues, DNA over extended periods. With the rising demand for long-term and secure storage solutions to support research in genomics, precision medicine, and regenerative therapies, biobanks are increasingly upgrading to state-of-the-art infrastructure.
A noteworthy development in this field is the launch of the BioArc™ Ultra by Azenta Life Sciences in February 2024. This system is tailor-made for large-scale biobanking needs, featuring a high-density, -80°C automated storage solution that boosts performance, saves energy, and optimizes space. Unlike traditional systems that depend on synthetic refrigerants, the BioArc Ultra uses a groundbreaking eco-friendly cooling method that relies on natural air, which means it has zero ozone depletion potential (ODP) and zero global warming potential (GWP). This not only ensures compliance with upcoming environmental regulations but also slashes electricity usage by up to 70%.
Blood products remain the most utilized sample type in the biobanking equipment market, owing to their extensive application in clinical research, personalized medicine, and transfusion-related studies. Their significance is underscored by their role in genetic research and the development of targeted therapies. From clinical trials and epidemiological studies to personalized medicine and transfusion science, blood samples serve as foundational material for investigating disease mechanisms, identifying biomarkers, and evaluating patient responses to treatment For instance, the Colorado Center for Personalized Medicine Biobank, a collaboration between UCHealth and the University of Colorado Anschutz Medical Campus, has collected blood samples from over 250,000 participants. This initiative has led to the identification of genetic risks for various conditions, including arrhythmogenic right ventricular cardiomyopathy (ARVC), enabling early intervention and personalized treatment plans. This is further propelling the biobanking equipment market demand.
There is a rising importance of regenerative medicine in the biobanking equipment market due to the more frequent use of stem cells and tissue engineering in curing chronic diseases and aiding with clinical trials. As medical science shifts toward personalized and regenerative treatments, the demand for high-quality, well-preserved biological samples especially stem cells has grown significantly. This need has led to the establishment of specialized stem cell biobanks, which are equipped with advanced storage systems capable of maintaining sample integrity over long periods. Because of an increased need for quality biosamples, this field now uses specialized stem cell biobanks. In 2024, the FDA approved Ryoncil™ as the first MSC therapy for children who do not respond to steroid treatment for severe GVHD. This further propels the demand for biobanking equipments.
Pharmaceutical companies are the main users of biobanking equipment, using these tools for drug discovery, identifying biomarkers, and managing samples for clinical trials. The demand for reliable and efficient sample processing in pharmaceutical research has spurred greater investments in cutting-edge biobanking infrastructure. As the pharmaceutical industry becomes increasingly data-driven and precision-focused, the need for reliable, high-throughput sample storage and processing systems has grown exponentially. In June 2023, PHC Corporation of North America introduced the PHCbi brand VIP ECO® SMART series of ultra-low temperature freezers, designed for use in pharmaceutical companies. This is further escalating the biobanking equipment market demand.
To learn more about this report, Download Free Sample
North America is expected to be the largest market for biobanking equipment market during the forecast period, accounting for over 47% of the market share in 2025. The market growth in North America is due to increasing product launches. PHC Corporation of North America announced the PHCbi Brand VIP ECO SMART Ultra-low Temperature Freezer in February 2023 which stands out for having some of the best energy efficiency. The region’s determination to include advanced technologies in biobanking is demonstrated by this launch.
The Europe market is expected to be the second-largest market for biobanking equipment market, accounting for over 27.3% of the market share in 2025. The market growth in Europe is due to increasing inorganic strategies by the market players. The UK Biobank launched the UK Biobank Pharma Proteomics Project (UKB-PPP) in January 2025 which aims to study every protein in human bodies. Within this initiative, scientists will measure up to 5,400 proteins in everyone of the 600,000 blood samples from the 500,000 participants and 100,000 extra samples collected 15 years after. The goal of the project is to look at how protein levels evolve with aging and affect the chance of developing certain illnesses. This is further expected to proliferate the biobanking equipment maret share.
India's biobanking equipment market is experiencing significant growth, propelled by the increasing demand for personalized medicine, advancements in genomic research, and the rising prevalence of chronic diseases. The surge in personalized healthcare approaches and genomic studies necessitates sophisticated biobanking equipment to store and manage diverse biological samples effectively. Rising number of biobanks across the country is also propelling the biobanking equipment market share. In December 2024, India established its first diabetes biobank. This cutting-edge facility, located at the Madras Diabetes Research Foundation in Chennai, is intended to support advanced diabetes research.
The United States biobanking equipment market is experiencing significant advancements, with IQVIA's Biobanking Solution playing a pivotal role in enhancing biospecimen management and supporting personalized medicine initiatives. IQVIA's Biobanking Solution offers a comprehensive, patient-centric platform that manages the entire lifecycle of biospecimens from extraction to analysis. By integrating data from various systems, including Hospital Information Systems and laboratory equipment, it creates longitudinal research records that provide meaningful contextual data for each sample. This approach transforms biobanks from mere storage facilities into valuable sources of knowledge for clinical research, further escalating the market growth.
In recent years, there has been a significant rise in investments that are made by academic medical centers, pharmaceutical companies, and contract research organizations towards advancing biobanking activities. The increased research and development (R&D) expenditure on biobanking is one of the key factors propelling the growth of the global biobanking equipment market. Major biobanking market players are investing heavily in order to build extensive biological sample collections that can support precision medicine initiatives and new drug development programs. For instance, in 2020, National Institutes of Health invested USD 130 million towards establishing six new biobanks across the U.S. as part of its All of Us Research Program (National Institutes of Health, 2020). These biobanks aim to gather genetic and health information from over a million volunteers to help accelerate research and provide insights into different diseases. Similarly, pharmaceutical giants are partnering with biobanks and investing in new warehouses, freezers, and automated storage solutions to store large volumes of samples collected from clinical trials.
Rising prevalence of chronic and infectious diseases across the globe is a major factor driving the growth of the biobanking equipment market. With more number of people suffering from life-threatening diseases such as cancer, cardiovascular diseases, diabetes and neurological disorders, the demand for biological samples for research purposes has increased exponentially. According to the US Department of Health and Human Services, approximately 129 million individuals in the United States suffer from at least one major chronic condition—such as heart disease, cancer, diabetes, obesity, or hypertension. Biobanks play a crucial role in collecting, processing, and storing biological samples which help researchers across academia and pharma companies to gain insights into the causes and progression of diseases and aid in the development of new diagnostic tools and treatment regimens. Rising incidence of such chronic and hard to treat diseases has accelerated the need for conducting extensive genomic and proteomic research on well-maintained biological samples stored in biobanks. This growing demand for samples is driving biobanks to expand their infrastructure with latest equipment such as sample analysis instruments, ultra-low temperature freezers, liquid nitrogen storage tanks, and other consumables.
Technological advancements in equipment present a great opportunity for growth in the global biobanking equipment market. As the demand for biobanking rises to support developments in precision medicine, cell therapy and other life science research areas, innovative equipment solutions will be critical to address the complex needs of biobanks. Biobanks are under constant pressure to store and process more samples while maintaining the highest standards of quality. Technologies that enhance automation, improve sample tracking procedures and enable around-the-clock operations can help biobanks scale up their activities more efficiently. For example, automated liquid handling robots and walk-in freezers with remote monitoring systems allow biobanks to load and retrieve samples faster without compromising accuracy or security. This boosts biobanks' sample throughput and frees up valuable technician time for higher-level tasks.
Growing demand for personalized medicine and precision diagnostics is driving significant growth in biomedical research and development activities. As the volume and complexity of biobank samples and associated data increases, there is a growing need for automated and high-throughput biobanking equipment that can efficiently process, store, and manage large volumes of samples and information. Automated systems allow for increased standardization, traceability, and scalability as compared to manual processes. Laboratories and biobanks are increasingly automating routine tasks such as sample accessioning, processing, aliquoting, storage, and retrieval to improve efficiency and minimize human errors.
In 2022, according to the American Type Culture Collection (ATCC) Annual Report, the American Type Culture Collection invested USD 15 million to build a new automated biorepository with robotic arms and automated storage systems that is capable of holding over 5 million frozen biomaterials. This underscores how automated technology enables expansion of biobanking operations to satisfy growing sample demand from pharmaceutical and diagnostic companies that is involved in precision drug development and clinical testing. The trend of increased automation in turn drives higher biobanking equipment market demand in the coming years.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.7 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 11.4% | 2032 Value Projection: | USD 7.88 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific, Brooks Automation, TTP Labtech, VWR International, Chart Industries, Sigma-Aldrich, Panasonic Healthcare, Thermo Fisher Scientific, Qiagen, and Hamilton Storage Technologies |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Recent Developments:In January 2025, a collaboration between the UK Biobank and more than a dozen pharmaceutical companies launched the world’s largest study of proteins in human blood. The project aims to analyze 5,400 proteins in blood samples from 500,000 people to better understand disease development and treatment.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
